Adamis Pharmaceuticals Corporation Stock Price, News & Analysis

Adamis Pharmaceuticals (NASDAQ: ADMP) announced new data supporting its ZIMHI™ product's dosage of naloxone hydrochloride. The findings suggest that ZIMHI's 5 mg dose is effective in resuscitating patients from high concentration fentanyl overdoses. This supports the FDA-approved ZIMHI as a critical tool in addressing rising opioid overdose deaths, now the leading cause of death for individuals under 50. The company collaborated with Rosa & Co. LLC on a study published in PLOS ONE, reinforcing the necessity of higher naloxone doses for effective treatment.

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has announced that it has regained compliance with NASDAQ Marketplace Rule 5250(c)(1). This follows the filing of its Quarterly Reports on Form 10-Q for the periods ended March 31, June 30, and September 30, 2021. As a result, the matter with NASDAQ is now closed. Adamis focuses on developing specialty products for allergy, opioid overdose, and respiratory diseases, with its approved SYMJEPI and ZIMHI injection products for emergency treatments.

Adamis Pharmaceuticals (NASDAQ: ADMP) reported financial results for the nine months ending September 30, 2021. Revenue increased to approximately $3.4 million from $2.1 million, driven by US WorldMeds' marketing of SYMJEPI. The FDA approved ZIMHI for opioid overdose, with a commercial launch expected in Q1 2022. The company has initiated a Phase 2/3 clinical trial for Tempol as a COVID-19 treatment. Selling, general, and administrative expenses rose to $13.2 million, while research and development expenses climbed to $9.1 million. Cash reserves stand at $28.7 million.

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) will host an investor conference call on November 22, 2021, at 2 p.m. PT to discuss its financial and operational results for the first nine months of 2021.

The company will release its financial results after 1 p.m. PT on the same day and will also file quarterly reports on Form 10-Q for the quarters ended March 31, June 30, and September 30, 2021. A live audio webcast will be available for investors.

Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) announced FDA approval for ZIMHI™, a high-dose naloxone injection (5 mg/0.5 mL), designed to treat opioid overdoses. This product aims to combat the rising opioid crisis, which has led to approximately 96,779 deaths in the U.S. over a year. The increased dosage provides a competitive edge over existing products, potentially enabling faster and more effective rescues. Commercial launch is planned for Q1 2022 in partnership with US WorldMeds, which will utilize its established infrastructure to address the urgent need for effective opioid overdose treatments.

Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) announced the appointment of Meera J. Desai, Ph.D., as a new director, effective October 1, 2021, replacing Roshawn Blunt. Dr. Desai brings substantial expertise in drug development and international licensing, expected to enhance corporate strategy and product pipeline refinement. She has a background with notable firms including AcelRx Pharmaceuticals and Novartis. Adamis focuses on developing products for various therapeutic areas, including allergy and opioid overdose, with its naloxone product currently under FDA review.

Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) commenced patient dosing in its Phase 2/3 clinical trial for Tempol, an oral antiviral for COVID-19, targeting 248 participants. The trial aims to evaluate Tempol's efficacy in hospitalized patients against a placebo. Preclinical studies indicated Tempol's antiviral and anti-inflammatory properties. The trial is timely amid rising COVID-19 cases, particularly with the delta variant. The NIH has recognized Tempol as a potential home treatment, emphasizing its ability to mitigate severe disease outcomes.

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced the appointment of David C. Benedicto as the new Chief Financial Officer, succeeding Robert O. Hopkins, who leaves after 14 years. Benedicto has been with the company for nearly seven years and holds extensive experience in finance within the biopharmaceutical sector. Additionally, Adamis received a notification from Nasdaq regarding non-compliance due to delayed filings of its Quarterly Reports, with a plan to regain compliance submitted to Nasdaq.

Adamis Pharmaceuticals has announced a study on Tempol, an investigational antioxidant, which demonstrates in-vitro anti-cytokine activity in COVID-19 patients. The publication in Clinical Immunology states that Tempol reduces harmful cytokines, suggesting its potential as a treatment for COVID-19. The NIH has recognized Tempol for its antiviral activity and plans for a clinical trial to evaluate its efficacy as a home treatment. The FDA has authorized this study, aiming to alleviate the strain on healthcare systems caused by COVID-19.